Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Want to cut your energy bills? Here’s how five experts are doing it 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SOUTH SAN FRANCISCO, Calif., May 25, 2017 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the Jefferies 2017 Global Healthcare Conference. Sean McCarthy, D.Phil., president and chief executive officer will deliver a corporate overview on June 7, 2017, at 3:00 p.m. ET.
A live audio webcast of the presentation will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. The Company uses its platform to create proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and develop first-in-class cancer therapeutics against difficult-to-drug targets, such as CD166. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The Company’s lead program, CX-072, a wholly-owned PD-L1-targeting Probody therapeutic, is being evaluated in a Phase 1/2 study. CX-072 is part of PROCLAIM (Probody Clinical Assessment In Man), an international umbrella clinical trial program that provides clinical trial sites with access to the Company’s novel therapies under one central protocol. The trial initiation for CX-2009, a first-in-class Probody drug conjugate targeting the highly expressed tumor antigen, CD166, is expected mid-2017. In addition to its proprietary programs, CytomX is collaborating with strategic partners, including AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
Media Contact: Canale Communications Ian Stone [email protected] 619-849-5388 Investor Contact: Trout Group Pete Rahmer [email protected] 646-378-2973
